Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the presentation of six posters, including the first interim real...
JMP Securities analyst Jonathan Wolleben maintains BioCryst Pharma (NASDAQ:BCRX) with a Market Outperform and raises the pri...
Barclays analyst Gena Wang maintains BioCryst Pharma (NASDAQ:BCRX) with a Equal-Weight and raises the price target from $6 t...
RBC Capital analyst Brian Abrahams reiterates BioCryst Pharma (NASDAQ:BCRX) with a Outperform and maintains $10 price target.
HC Wainwright & Co. analyst Andrew Fein reiterates BioCryst Pharma (NASDAQ:BCRX) with a Buy and maintains $30 price target.
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced new real-world evidence showing that patients with hereditary angi...
